Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
Foghorn Therapeutics (NASDAQ: FHTX) has announced a virtual investor event scheduled for April 29, 2025, at 8:00 a.m. ET to discuss key pipeline updates coinciding with the 2025 AACR Annual Meeting.
The company will present new preclinical combination data for FHD-909 (LY4050784), their potential first-in-class selective SMARCA2 inhibitor, targeting primarily non-small cell lung cancer (NSCLC). Additionally, Foghorn will share updates on their:
- Selective CBP degrader program's preclinical data in combination with chemotherapy and targeted agents
- Selective EP300 degrader program in hematological malignancies
- Selective ARID1B degrader program overview
The virtual event will review presentations from the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025. The webcast will be available on Foghorn's website with replay access post-event.
Foghorn Therapeutics (NASDAQ: FHTX) ha annunciato un evento virtuale per investitori previsto per il 29 aprile 2025 alle 8:00 ET, durante il quale verranno discussi aggiornamenti chiave sul loro pipeline in concomitanza con il congresso annuale AACR 2025.
L'azienda presenterà nuovi dati preclinici sulla combinazione di FHD-909 (LY4050784), il loro potenziale inibitore selettivo SMARCA2 di prima classe, rivolto principalmente al carcinoma polmonare non a piccole cellule (NSCLC). Inoltre, Foghorn fornirà aggiornamenti sui seguenti programmi:
- Dati preclinici del programma selettivo di degradazione CBP in combinazione con chemioterapia e agenti mirati
- Programma selettivo di degradazione EP300 nelle neoplasie ematologiche
- Panoramica del programma selettivo di degradazione ARID1B
L’evento virtuale includerà la revisione delle presentazioni del congresso annuale 2025 dell’American Association for Cancer Research (AACR), che si terrà dal 25 al 30 aprile 2025. Il webcast sarà disponibile sul sito di Foghorn con accesso alla replica dopo l’evento.
Foghorn Therapeutics (NASDAQ: FHTX) ha anunciado un evento virtual para inversores programado para el 29 de abril de 2025 a las 8:00 a.m. ET, donde se discutirán actualizaciones clave del pipeline coincidiendo con la Reunión Anual AACR 2025.
La compañía presentará nuevos datos preclínicos en combinación para FHD-909 (LY4050784), su posible primer inhibidor selectivo SMARCA2 de su clase, dirigido principalmente al cáncer de pulmón no microcítico (NSCLC). Además, Foghorn compartirá actualizaciones sobre sus:
- Datos preclínicos del programa selectivo de degradación CBP en combinación con quimioterapia y agentes dirigidos
- Programa selectivo de degradación EP300 en malignidades hematológicas
- Resumen del programa selectivo de degradación ARID1B
El evento virtual revisará las presentaciones de la Reunión Anual 2025 de la American Association for Cancer Research (AACR), que se realizará del 25 al 30 de abril de 2025. La transmisión estará disponible en el sitio web de Foghorn con acceso a la repetición después del evento.
Foghorn Therapeutics (NASDAQ: FHTX)는 2025년 4월 29일 오전 8시(동부시간)에 가상 투자자 이벤트를 개최하여 2025년 AACR 연례회의와 맞물려 주요 파이프라인 업데이트를 논의할 예정입니다.
회사는 주로 비소세포폐암(NSCLC)을 겨냥한 잠재적 최초의 선택적 SMARCA2 억제제인 FHD-909 (LY4050784)의 새로운 전임상 병용 데이터들을 발표할 예정입니다. 또한, Foghorn은 다음 프로그램에 대한 업데이트를 공유할 것입니다:
- 항암화학요법 및 표적제와 병용한 선택적 CBP 분해제 프로그램의 전임상 데이터
- 혈액암에서의 선택적 EP300 분해제 프로그램
- 선택적 ARID1B 분해제 프로그램 개요
가상 이벤트에서는 2025년 4월 25일부터 30일까지 개최되는 미국암연구학회(AACR) 연례회의 발표 내용을 검토할 예정이며, 웨비캐스트는 Foghorn 웹사이트에서 제공되며 행사 후 재시청이 가능합니다.
Foghorn Therapeutics (NASDAQ : FHTX) a annoncé un événement virtuel pour les investisseurs prévu le 29 avril 2025 à 8h00 ET afin de présenter des mises à jour clés de leur pipeline, en lien avec la réunion annuelle AACR 2025.
La société présentera de nouvelles données précliniques en combinaison pour FHD-909 (LY4050784), leur potentiel inhibiteur sélectif SMARCA2 de première classe, ciblant principalement le cancer du poumon non à petites cellules (NSCLC). De plus, Foghorn partagera des mises à jour sur leurs programmes :
- Données précliniques du programme de dégradation sélective de CBP en combinaison avec chimiothérapie et agents ciblés
- Programme de dégradation sélective d’EP300 dans les hémopathies malignes
- Présentation du programme de dégradation sélective d’ARID1B
L’événement virtuel passera en revue les présentations de la réunion annuelle 2025 de l’American Association for Cancer Research (AACR), qui se tiendra du 25 au 30 avril 2025. Le webcast sera disponible sur le site de Foghorn avec un accès en replay après l’événement.
Foghorn Therapeutics (NASDAQ: FHTX) hat eine virtuelle Investorenveranstaltung für den 29. April 2025 um 8:00 Uhr ET angekündigt, um wichtige Updates zur Pipeline im Zusammenhang mit dem AACR-Jahrestreffen 2025 zu besprechen.
Das Unternehmen wird neue präklinische Kombinationsdaten für FHD-909 (LY4050784) präsentieren, ihren potenziellen ersten selektiven SMARCA2-Inhibitor seiner Art, der hauptsächlich auf nicht-kleinzelligen Lungenkrebs (NSCLC) abzielt. Zusätzlich wird Foghorn Updates zu folgenden Programmen vorstellen:
- Präklinische Daten des selektiven CBP-Degrader-Programms in Kombination mit Chemotherapie und zielgerichteten Wirkstoffen
- Selektives EP300-Degrader-Programm bei hämatologischen Malignomen
- Überblick über das selektive ARID1B-Degrader-Programm
Die virtuelle Veranstaltung wird Präsentationen des 2025 American Association for Cancer Research (AACR) Jahrestreffens, das vom 25. bis 30. April 2025 stattfindet, überprüfen. Der Webcast wird auf der Website von Foghorn verfügbar sein, mit Wiedergabezugang nach der Veranstaltung.
- None.
- None.
Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population
Additional updates include new preclinical data for Selective CBP degrader program in combination with chemotherapy and targeted agents and for Selective EP300 degrader program in hematological malignancies
Virtual investor event to be held on Tuesday April 29, 2025, at 8 a.m. ET
CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will host a virtual investor event on April 29th at 8:00 a.m. ET to review key pipeline updates in conjunction with the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025.
Foghorn management will review updates for FHD-909, a potential first-in-class selective SMARCA2 inhibitor, including new preclinical combination data being presented at the 2025 AACR Annual Meeting. In addition, the company will share new preclinical data from their Selective CBP degrader and Selective EP300 degrader programs and provide an overview of their Selective ARID1B degrader program. The details of Foghorn’s upcoming oral and poster presentations at AACR 2025 can be found here.
Investor Event Information
Please click here to register for the virtual investor event on Tuesday, April 29, 2025. The live webcast will also be available under the Events & Presentations section of Foghorn’s website. A replay of the event and presentation will be available immediately following the event.
About FHD-909
FHD-909 (LY4050784) is a potent, first-in-class, allosteric and orally available small molecule that selectively inhibits the ATPase activity of SMARCA2 (BRM) over its closely related paralog SMARCA4 (BRG1), two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, tumors with mutations in SMARCA4 rely on SMARCA2 for BAF function. FHD-909 has shown significant anti-tumor activity across multiple SMARCA4 mutant lung tumor models.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, including the ongoing Phase 1 trial evaluating FHD-909, a first-in-class oral selective SMARCA2 inhibitor, in SMARCA4 mutated cancers, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
What new data will Foghorn (FHTX) present for FHD-909 at AACR 2025?
When is Foghorn Therapeutics (FHTX) hosting their virtual investor event for AACR 2025 updates?
What pipeline programs will FHTX discuss during their April 2025 investor event?
What is the primary target population for Foghorn's FHD-909 drug candidate?
Where can investors access Foghorn's AACR 2025 virtual presentation?
